Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Researchers have presented findings from the first large cohort of people followed over a lengthy period to assess this connection.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
The drug is still associated with a lower liver cancer rate than Baraclude.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
Researchers compared liver-related death rates among Mexicans, Puerto Ricans and Cubans.
Opioid overdoses kill more Americans than car crashes, drowning, fire, and falls.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
Treating hep C lowers the risk.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
That is compared with people who have hep C who had other types of insurance coverage.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
This is according to a recent mathematical modeling study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.